Literature DB >> 25394490

GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein.

J J Credle1, J L George2, J Wills1, V Duka1, K Shah1, Y-C Lee3, O Rodriguez3, T Simkins4, M Winter1, D Moechars5, T Steckler5, J Goudreau4, D I Finkelstein2, A Sidhu1.   

Abstract

Aberrant posttranslational modifications (PTMs) of proteins, namely phosphorylation, induce abnormalities in the biological properties of recipient proteins, underlying neurological diseases including Parkinson's disease (PD). Genome-wide studies link genes encoding α-synuclein (α-Syn) and Tau as two of the most important in the genesis of PD. Although several kinases are known to phosphorylate α-Syn and Tau, we focused our analysis on GSK-3β because of its accepted role in phosphorylating Tau and to increasing evidence supporting a strong biophysical relationship between α-Syn and Tau in PD. Therefore, we investigated transgenic mice, which express a point mutant (S9A) of human GSK-3β. GSK-3β-S9A is capable of activation through endogenous natural signaling events, yet is unable to become inactivated through phosphorylation at serine-9. We used behavioral, biochemical, and in vitro analysis to assess the contributions of GSK-3β to both α-Syn and Tau phosphorylation. Behavioral studies revealed progressive age-dependent impairment of motor function, accompanied by loss of tyrosine hydroxylase-positive (TH+ DA-neurons) neurons and dopamine production in the oldest age group. Magnetic resonance imaging revealed deterioration of the substantia nigra in aged mice, a characteristic feature of PD patients. At the molecular level, kinase-active p-GSK-3β-Y216 was seen at all ages throughout the brain, yet elevated levels of p-α-Syn-S129 and p-Tau (S396/404) were found to increase with age exclusively in TH+ DA-neurons of the midbrain. p-GSK-3β-Y216 colocalized with p-Tau and p-α-Syn-S129. In vitro kinase assays showed that recombinant human GSK-3β directly phosphorylated α-Syn at a single site, Ser129, in addition to its known ability to phosphorylate Tau. Moreover, α-Syn and Tau together cooperated with one another to increase the magnitude or rate of phosphorylation of the other by GSK-3β. Together, these data establish a novel upstream role for GSK-3β as one of several kinases associated with PTMs of key proteins known to be causal in PD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25394490      PMCID: PMC4392080          DOI: 10.1038/cdd.2014.179

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  70 in total

1.  A chaperone-dependent GSK3beta transitional intermediate mediates activation-loop autophosphorylation.

Authors:  Pamela A Lochhead; Ross Kinstrie; Gary Sibbet; Teeara Rawjee; Nick Morrice; Vaughn Cleghon
Journal:  Mol Cell       Date:  2006-11-17       Impact factor: 17.970

2.  SNCA, MAPT, and GSK3B in Parkinson disease: a gene-gene interaction study.

Authors:  C Wider; C Vilariño-Güell; M G Heckman; B Jasinska-Myga; A I Ortolaza-Soto; N N Diehl; J E Crook; S A Cobb; J A Bacon; J O Aasly; J M Gibson; T Lynch; R J Uitti; Z K Wszolek; M J Farrer; O A Ross
Journal:  Eur J Neurol       Date:  2010-12-15       Impact factor: 6.089

3.  Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis.

Authors:  P Riederer; S Wuketich
Journal:  J Neural Transm       Date:  1976       Impact factor: 3.575

4.  GSK3B polymorphisms alter transcription and splicing in Parkinson's disease.

Authors:  John B J Kwok; Marianne Hallupp; Clement T Loy; Daniel K Y Chan; Jean Woo; George D Mellick; Daniel D Buchanan; Peter A Silburn; Glenda M Halliday; Peter R Schofield
Journal:  Ann Neurol       Date:  2005-12       Impact factor: 10.422

5.  Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease.

Authors:  John P Anderson; Donald E Walker; Jason M Goldstein; Rian de Laat; Kelly Banducci; Russell J Caccavello; Robin Barbour; Jiping Huang; Kristin Kling; Michael Lee; Linnea Diep; Pamela S Keim; Xiaofeng Shen; Tim Chataway; Michael G Schlossmacher; Peter Seubert; Dale Schenk; Sukanto Sinha; Wei Ping Gai; Tamie J Chilcote
Journal:  J Biol Chem       Date:  2006-07-17       Impact factor: 5.157

6.  Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein.

Authors:  Katerina E Paleologou; Adrian W Schmid; Carla C Rospigliosi; Hai-Young Kim; Gonzalo R Lamberto; Ross A Fredenburg; Peter T Lansbury; Claudio O Fernandez; David Eliezer; Markus Zweckstetter; Hilal A Lashuel
Journal:  J Biol Chem       Date:  2008-03-14       Impact factor: 5.157

7.  Glycogen synthase kinase-3 beta phosphorylates tau protein at multiple sites in intact cells.

Authors:  B R Sperber; S Leight; M Goedert; V M Lee
Journal:  Neurosci Lett       Date:  1995-09-08       Impact factor: 3.046

8.  Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models.

Authors:  Tetyana Duka; Valeriy Duka; Jeffrey N Joyce; Anita Sidhu
Journal:  FASEB J       Date:  2009-04-15       Impact factor: 5.191

9.  Neonatal neuronal overexpression of glycogen synthase kinase-3 beta reduces brain size in transgenic mice.

Authors:  K Spittaels; C Van den Haute; J Van Dorpe; D Terwel; K Vandezande; R Lasrado; K Bruynseels; M Irizarry; M Verhoye; J Van Lint; J R Vandenheede; D Ashton; M Mercken; R Loos; B Hyman; A Van der Linden; H Geerts; F Van Leuven
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

10.  Substantia nigra volume loss before basal forebrain degeneration in early Parkinson disease.

Authors:  David A Ziegler; Julien S Wonderlick; Paymon Ashourian; Leslie A Hansen; Jeremy C Young; Alex J Murphy; Cecily K Koppuzha; John H Growdon; Suzanne Corkin
Journal:  JAMA Neurol       Date:  2013-02       Impact factor: 18.302

View more
  26 in total

1.  Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice.

Authors:  A M Willard; R S Bouchard; A H Gittis
Journal:  Neuroscience       Date:  2015-06-09       Impact factor: 3.590

2.  Role of GSK3β/α-synuclein axis in methamphetamine-induced neurotoxicity in PC12 cells.

Authors:  Lizeng Li; Si Chen; Yue Wang; Xia Yue; Jingtao Xu; Weibing Xie; Pingming Qiu; Chao Liu; AiFeng Wang; Huijun Wang
Journal:  Toxicol Res (Camb)       Date:  2017-12-22       Impact factor: 3.524

3.  Sustained Effects of Neonatal Systemic Lipopolysaccharide on IL-1β and Nrf2 in Adult Rat Substantia Nigra Are Partly Normalized by a Spirulina-Enriched Diet.

Authors:  Jaspal Patil; Ashok Matte; Hans Nissbrandt; Carina Mallard; Mats Sandberg
Journal:  Neuroimmunomodulation       Date:  2016-12-09       Impact factor: 2.492

4.  Glycogen Synthase Kinase-3β Regulates Equilibrium Between Neurogenesis and Gliogenesis in Rat Model of Parkinson's Disease: a Crosstalk with Wnt and Notch Signaling.

Authors:  Sonu Singh; Akanksha Mishra; Sachi Bharti; Virendra Tiwari; Jitendra Singh; Shubha Shukla
Journal:  Mol Neurobiol       Date:  2018-01-11       Impact factor: 5.590

5.  Rifampicin Prevents SH-SY5Y Cells from Rotenone-Induced Apoptosis via the PI3K/Akt/GSK-3β/CREB Signaling Pathway.

Authors:  Xia Wu; Yanran Liang; Xiuna Jing; Danyu Lin; Ying Chen; Tianen Zhou; Sudan Peng; Dezhi Zheng; Zhifen Zeng; Ming Lei; Kaixun Huang; Enxiang Tao
Journal:  Neurochem Res       Date:  2018-02-12       Impact factor: 3.996

6.  Chlorogenic Acid: a Polyphenol from Coffee Rendered Neuroprotection Against Rotenone-Induced Parkinson's Disease by GLP-1 Secretion.

Authors:  Nishant Sharma; Ritu Soni; Monika Sharma; Sayan Chatterjee; Nidhi Parihar; Mohd Mukarram; Ruhi Kale; Adil Ali Sayyed; Santosh Kumar Behera; Amit Khairnar
Journal:  Mol Neurobiol       Date:  2022-09-01       Impact factor: 5.682

7.  Neurotrophin Expression in Lymphocytes: a Powerful Indicator of Degeneration in Parkinson's Disease, Amyotrophic Lateral Sclerosis and Ataxia.

Authors:  Anjana Sadanand; Anjali Janardhanan; A J Vanisree; Thamil Pavai
Journal:  J Mol Neurosci       Date:  2017-12-16       Impact factor: 3.444

Review 8.  Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis.

Authors:  Phuong H Nguyen; Ayyalusamy Ramamoorthy; Bikash R Sahoo; Jie Zheng; Peter Faller; John E Straub; Laura Dominguez; Joan-Emma Shea; Nikolay V Dokholyan; Alfonso De Simone; Buyong Ma; Ruth Nussinov; Saeed Najafi; Son Tung Ngo; Antoine Loquet; Mara Chiricotto; Pritam Ganguly; James McCarty; Mai Suan Li; Carol Hall; Yiming Wang; Yifat Miller; Simone Melchionna; Birgit Habenstein; Stepan Timr; Jiaxing Chen; Brianna Hnath; Birgit Strodel; Rakez Kayed; Sylvain Lesné; Guanghong Wei; Fabio Sterpone; Andrew J Doig; Philippe Derreumaux
Journal:  Chem Rev       Date:  2021-02-05       Impact factor: 60.622

9.  Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases.

Authors:  Stephen N Gomperts; Joseph J Locascio; Sara J Makaretz; Aaron Schultz; Christina Caso; Neil Vasdev; Reisa Sperling; John H Growdon; Bradford C Dickerson; Keith Johnson
Journal:  JAMA Neurol       Date:  2016-11-01       Impact factor: 18.302

10.  GSK-3β-induced Tau pathology drives hippocampal neuronal cell death in Huntington's disease: involvement of astrocyte-neuron interactions.

Authors:  F L'Episcopo; J Drouin-Ouellet; C Tirolo; A Pulvirenti; R Giugno; N Testa; S Caniglia; M F Serapide; G Cisbani; R A Barker; F Cicchetti; B Marchetti
Journal:  Cell Death Dis       Date:  2016-04-28       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.